



Polarean Imaging Plc
("Polarean" or the "Company")

PDMR Dealing

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces it has received notification today from Bill Blair, an Independent Non-Executive Director ("NED") who is considered by the Company to be a person discharging managerial responsibility ("PDMR"), that he sold 650,000 ordinary shares of £0.00037 each in the capital of the Company ("Ordinary Shares") on 17 July 2024 and 2,039 Ordinary Shares on 18 July 2024, all at a price of 1.8p per Ordinary Share.

Notifications have been made in accordance with the requirements of the UK Market Abuse Regulation in respect of the PDMR and further details can be found by following this link: <https://www.polarean-ir.com/content/investors/shareholder-information>

Enquiries:

Polarean Imaging plc
Christopher von Jako, Ph.D, Chief Executive Officer
Charles Osborne, Chief Financial Officer

www.polarean.com / www.polarean-ir.com
Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)
Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)
Nick Harland (Corporate Broking)

+44 (0)20 7710 7600

Walbrook PR
Anna Dunphy / Phillip Marriage

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

About Polarean

Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHQKFBNABKDBOD